Currently Viewing:
Currently Reading
In Small Amount of Patients, CD4+ T Cells Continue to Decline Despite Being Virally Suppressed
April 18, 2019 – Jaime Rosenberg
Shoshana Lipson Explains How "CGRP & Migraine Community" Supports Patients
April 18, 2019
Is Immunotherapy the Key to Developing an HIV Vaccine?
April 18, 2019 – Wallace Stephens
What We're Reading: Doctors Charged in Opioid Scheme; First US CRISPR Treatment; "Bubble Boy" Disease Cured
April 18, 2019 – AJMC Staff
Dim Light at Night May Help Spread Breast Cancer to Bones
April 18, 2019 – Laura Joszt
Cytomegalovirus May Speed Disease Progression in Cystic Fibrosis
April 17, 2019 – Jaime Rosenberg
Evaluating Revefenacin as a Treatment for COPD
April 17, 2019 – Wallace Stephens
Humana Launches Payment Model to Improve Patient Experience, Outcomes in Cancer Care
April 17, 2019 – Jaime Rosenberg
Bill Seeks to Ban Online Sales of e-Cigarettes, Raise Age to Buy Tobacco to 21
April 17, 2019 – Allison Inserro

FDA Grants Priority Review for Lilly's Verzenio for Metastatic Breast Cancer

Alison Rodriguez
The FDA has granted Priority Review designation for Eli Lilly and Company’s New Drug Application (NDA) for Verzenio (abemaciclib), a cyclindependent kinase 4 and 6 inhibitor for metastatic breast cancer. The decision was based on the MONARCH 3 study, which examined abemaciclib as an initial endocrine-based therapy.
The FDA has granted Priority Review designation for Eli Lilly and Company’s New Drug Application (NDA) for Verzenio (abemaciclib), a cyclindependent kinase (CDK) 4 and 6 inhibitor for metastatic breast cancer.

The FDA’s decision was based on the positive interim results of the MONARCH 3 study, which examined abemaciclib in combination with an aromatase inhibitor as initial endocrine-based therapy for treating women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced or metastatic breast cancer.

"On the heels of our recent FDA approval of Verzenio, we are pleased with this important step forward in the agency's consideration to expand the use of Verzenio in metastatic breast cancer," Levi Garraway, MD, PhD, senior vice president, global development and medical affairs, Lilly Oncology, said in a statement. "We look forward to ongoing collaboration with the FDA to advance this important treatment across the spectrum of care for patients living with advanced or metastatic breast cancer." 

Verzenio was developed to disrupt the cell cycle. When dosed daily as a single agent or in combination with antiestrogens, the treatment has been found to reduce tumor size in patients. This treatment could potentially be used to treat breast cancer—the most frequently diagnosed cancer in women worldwide.

The MONARCH 3 study results were originally presented at the European Society for Medical Oncology (ESMO) 2017 Congress, and later published in the Journal of Clinical Oncology.

"The significant results seen in MONARCH 3 confirm the clinical value of combining abemaciclib with an aromatase inhibitor in patients with endocrine-sensitive advanced breast cancer, and we look forward to seeing the final PFS data in the coming months," lead author Matthew P. Goetz, MD, professor of oncology and pharmacology at Mayo Clinic and co-lead investigator of the MONARCH 3 study, said in a statement. "These data further demonstrate that abemaciclib is an effective treatment in the CDK4 and 6 class. This class represents a new standard of care in the treatment of advanced breast cancer."

The Priority Review that the FDA granted Verzenio is intended to expedite the review of applications for the drug due to the significance advance in treatment. Additionally, Priority Review of a new drug allows the FDA to take action within 8 months of receiving the application while the standard review time is 12 months.

Copyright AJMC 2006-2018 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
Welcome the the new and improved, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up